IL7R and myeloid sarcoma: In 2018, a Bioinformatics study has identified miR-199a and miR-142–3-P as crucial biomarkers in MS due to targeting the pivotal susceptibility genes, in particular KRAS and IL7R. They also examined IL7R expression in a small population of MS and control patients (15 MS, 14 controls) and reported an increased expression of this gene, which contradicts our study33.